{"DataElement":{"publicId":"3191476","version":"1","preferredName":"Antiplatelet Agent At Hospital Administration Type","preferredDefinition":"Type of the antiplatelet medications that inhibit platelet aggregation and reduce coagulation in the circulatory system received in hospital.","longName":"APLTLT_HSP_TYP","context":"NCIP","contextVersion":"1","DataElementConcept":{"publicId":"3191448","version":"1","preferredName":"Antiplatelet Agent At Hospital Administration","preferredDefinition":"Administration of an agent that inhibits platelet aggregation and reduces coagulation in the circulatory system in hospital.","longName":"APLTLT_ADMN_HSP","context":"NCIP","contextVersion":"1","ObjectClass":{"publicId":"3191446","version":"1","preferredName":"Antiplatelet Agent","preferredDefinition":"An agent that inhibits platelet aggregation and reduces coagulation in the circulatory system. (NCI)","longName":"C1327","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Antiplatelet Agent","conceptCode":"C1327","definition":"An agent that inhibits platelet aggregation and reduces coagulation in the circulatory system.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9BF5C7EE-E688-1E67-E040-BB89AD4359EB","latestVersionIndicator":"Yes","beginDate":"2011-02-10","endDate":null,"createdBy":"LUY","dateCreated":"2011-02-10","modifiedBy":"ONEDATA","dateModified":"2011-02-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3191437","version":"1","preferredName":"At Hospital Administration","preferredDefinition":"Used to indicate position, location, or state (American Heritage Dictionary):An institution that provides medical, surgical, or psychiatric care and treatment for the sick or the injured.:The act of administration.","longName":"C25427:C16696:C25409","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"At","conceptCode":"C25427","definition":"Used to indicate position, location, or state.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Hospital","conceptCode":"C16696","definition":"An institution that provides medical, surgical, or psychiatric care and treatment for the sick or the injured.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Administration","conceptCode":"C25409","definition":"The act of the dispensing, applying, or tendering of something to another, such as administration of a medicine.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9BF56B2C-CB32-4116-E040-BB89AD434EBE","latestVersionIndicator":"Yes","beginDate":"2011-02-10","endDate":null,"createdBy":"LUY","dateCreated":"2011-02-10","modifiedBy":"ONEDATA","dateModified":"2011-02-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2435024","version":"1","preferredName":"Drug or Chemical","preferredDefinition":"A category of organic or inorganic substances, elements, and isotopes used in research or for the prevention, diagnosis, and/or treatment of disease states. Includes biologically active substances that are either synthetically manufactured or endogenous substances extracted and processed to be reintroduced into an organism. Chemicals and drugs also include hazardous substances, and naturally occurring or synthetically produced substances required to maintain life.","longName":"C1908","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"07431EBC-FB04-25D9-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NINDS:National Institute of Neurological Disorders and Stroke Common Data Element Project","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9BF5C7EE-E696-1E67-E040-BB89AD4359EB","latestVersionIndicator":"Yes","beginDate":"2011-02-10","endDate":null,"createdBy":"LUY","dateCreated":"2011-02-10","modifiedBy":"TSESU","dateModified":"2018-05-25","changeDescription":"5/25/18 - smt CDE transferred to NCIP ownership per NINDS (Muniza Sheikh) request.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3191450","version":"1","preferredName":"Antiplatelet Agent Type","preferredDefinition":"Type of an agent that inhibits platelet aggregation and reduces coagulation in the circulatory system.","longName":"APLTLT_TYP","context":"NCIP","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":null,"minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"2946060","version":"1","preferredName":"Other","longName":"2946060","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"746A8063-D650-3C9D-E040-BB89AD437A9B","latestVersionIndicator":"Yes","beginDate":"2009-09-25","endDate":null,"createdBy":"AHMEDS","dateCreated":"2009-09-25","modifiedBy":"GDEEN","dateModified":"2024-01-19","changeDescription":null,"administrativeNotes":"1/25/23 added alt name for ticket number CADSR0001948 for CCTG cjl.","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9BF5C7EE-E8A7-1E67-E040-BB89AD4359EB","beginDate":"2011-02-10","endDate":null,"createdBy":"LUY","dateCreated":"2011-02-10","modifiedBy":"SBR","dateModified":"2018-12-20","deletedIndicator":"No"},{"value":"Ticlopidine (Ticlid)","valueDescription":"Ticlopidine","ValueMeaning":{"publicId":"3191451","version":"1","preferredName":"Ticlopidine","longName":"3191451v1.00","preferredDefinition":"A thienopyridine derivative with anticoagulant activity. Ticlopidine inhibits adenosine-diphosphate (ADP) binding to its platelet receptor. This prevents ADP activation and inhibits platelet expression of the glycoprotein (GP) IIb/IIIA receptors, binding of fibrinogen to platelet glycoprotein GP IIb-IIIa and platelet-platelet interaction. This results in increased bleeding time.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ticlopidine","conceptCode":"C61972","definition":"A thienopyridine derivative with anticoagulant activity. Ticlopidine inhibits adenosine-diphosphate (ADP) binding to its platelet receptor. This prevents ADP activation and inhibits platelet expression of the glycoprotein (GP) IIb/IIIA receptors, binding of fibrinogen to platelet glycoprotein GP IIb-IIIa and platelet-platelet interaction. This results in increased bleeding time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9BF5C7EE-E8B3-1E67-E040-BB89AD4359EB","latestVersionIndicator":"Yes","beginDate":"2011-02-10","endDate":null,"createdBy":"LUY","dateCreated":"2011-02-10","modifiedBy":"KUMMEROA","dateModified":"2023-08-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9BF5C7EE-E8CC-1E67-E040-BB89AD4359EB","beginDate":"2011-02-10","endDate":null,"createdBy":"LUY","dateCreated":"2011-02-10","modifiedBy":"SBR","dateModified":"2018-12-20","deletedIndicator":"No"},{"value":"Clopidogrel (Plavix)","valueDescription":"Clopidogrel","ValueMeaning":{"publicId":"3191453","version":"1","preferredName":"Clopidogrel","longName":"3191453v1.00","preferredDefinition":"A thienopyridine, with antiplatelet activity. Clopidogrel targets, irreversibly binds to and alters the platelet receptor for adenosine diphosphate (ADP), thereby blocking the binding of ADP to its receptor, inhibiting ADP-mediated activation of the glycoprotein complex GPIIb/IIIa, and inhibiting fibrinogen binding to platelets and platelet adhesion and aggregation. This results in increased bleeding time.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clopidogrel","conceptCode":"C61686","definition":"A thienopyridine, with antiplatelet activity. Clopidogrel targets, irreversibly binds to and alters the platelet receptor for adenosine diphosphate (ADP), thereby blocking the binding of ADP to its receptor, inhibiting ADP-mediated activation of the glycoprotein complex GPIIb/IIIa, and inhibiting fibrinogen binding to platelets and platelet adhesion and aggregation. This results in increased bleeding time.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9BF5C7EE-E8D9-1E67-E040-BB89AD4359EB","latestVersionIndicator":"Yes","beginDate":"2011-02-10","endDate":null,"createdBy":"LUY","dateCreated":"2011-02-10","modifiedBy":"KUMMEROA","dateModified":"2023-08-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9BF5C7EE-E8F2-1E67-E040-BB89AD4359EB","beginDate":"2011-02-10","endDate":null,"createdBy":"LUY","dateCreated":"2011-02-10","modifiedBy":"SBR","dateModified":"2018-12-20","deletedIndicator":"No"},{"value":"Aspirin/Dipyridamole","valueDescription":"Acetylsalicylic Acid Dipyridamole","ValueMeaning":{"publicId":"3191454","version":"1","preferredName":"Acetylsalicylic Acid Dipyridamole","longName":"3191454","preferredDefinition":"An orally administered non-steroidal antiinflammatory agent that inhibits cyclooxygenase synthesis of prostaglandin, preventing the formation of platelet aggregation and inflammation. It has analgesic and antipyretic properties. (NCI04): A drug that prevents blood cell clumping and enhances the effectiveness of fluorouracil and other chemotherapeutic agents.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Aspirin","conceptCode":"C287","definition":"An orally administered non-steroidal antiinflammatory agent. Acetylsalicylic acid binds to and acetylates serine residues in cyclooxygenases, resulting in decreased synthesis of prostaglandin, platelet aggregation, and inflammation. This agent exhibits analgesic, antipyretic, and anticoagulant properties.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Dipyridamole","conceptCode":"C445","definition":"A synthetic agent derivative of pyrimido-pyrimidine, with antiplatelet properties.  Dipyridamole inhibits adenosine uptake by platelets and endothelial cells, triggering an accumulation of cyclic adenosine monophosphate (cAMP), and inhibiting the stimulation of platelet aggregation by agents such as platelet activating factor and collagen. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9BF5C7EE-E8FF-1E67-E040-BB89AD4359EB","latestVersionIndicator":"Yes","beginDate":"2011-02-10","endDate":null,"createdBy":"LUY","dateCreated":"2011-02-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9BF5C7EE-E918-1E67-E040-BB89AD4359EB","beginDate":"2011-02-10","endDate":null,"createdBy":"LUY","dateCreated":"2011-02-10","modifiedBy":"SBR","dateModified":"2018-12-20","deletedIndicator":"No"},{"value":"Aspirin","valueDescription":"Acetylsalicylic Acid","ValueMeaning":{"publicId":"2576901","version":"1","preferredName":"Acetylsalicylic Acid","longName":"2576901","preferredDefinition":"An orally administered non-steroidal antiinflammatory agent that inhibits cyclooxygenase synthesis of prostaglandin, preventing the formation of platelet aggregation and inflammation. It has analgesic and antipyretic properties. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Aspirin","conceptCode":"C287","definition":"An orally administered non-steroidal antiinflammatory agent. Acetylsalicylic acid binds to and acetylates serine residues in cyclooxygenases, resulting in decreased synthesis of prostaglandin, platelet aggregation, and inflammation. This agent exhibits analgesic, antipyretic, and anticoagulant properties.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F972-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-24","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-24","modifiedBy":"REEVESD","dateModified":"2005-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9BF5C7EE-E92C-1E67-E040-BB89AD4359EB","beginDate":"2011-02-10","endDate":null,"createdBy":"LUY","dateCreated":"2011-02-10","modifiedBy":"SBR","dateModified":"2018-12-20","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2435024","version":"1","preferredName":"Drug or Chemical","preferredDefinition":"A category of organic or inorganic substances, elements, and isotopes used in research or for the prevention, diagnosis, and/or treatment of disease states. Includes biologically active substances that are either synthetically manufactured or endogenous substances extracted and processed to be reintroduced into an organism. Chemicals and drugs also include hazardous substances, and naturally occurring or synthetically produced substances required to maintain life.","longName":"C1908","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"07431EBC-FB04-25D9-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3191449","version":"1","preferredName":"Antiplatelet Agent Type","preferredDefinition":"An agent that inhibits platelet aggregation and reduces coagulation in the circulatory system. (NCI):Type; a subdivision of a particular kind of thing.","longName":"C1327:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Antiplatelet Agent","conceptCode":"C1327","definition":"An agent that inhibits platelet aggregation and reduces coagulation in the circulatory system.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9BF5C7EE-E883-1E67-E040-BB89AD4359EB","latestVersionIndicator":"Yes","beginDate":"2011-02-10","endDate":null,"createdBy":"LUY","dateCreated":"2011-02-10","modifiedBy":"ONEDATA","dateModified":"2011-02-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NINDS:National Institute of Neurological Disorders and Stroke Common Data Element Project","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9BF5C7EE-E894-1E67-E040-BB89AD4359EB","latestVersionIndicator":"Yes","beginDate":"2011-02-10","endDate":null,"createdBy":"LUY","dateCreated":"2011-02-10","modifiedBy":"KUMMEROA","dateModified":"2023-08-21","changeDescription":"5/25/18 - smt CDE transferred to NCIP ownership per NINDS (Muniza Sheikh) request.","administrativeNotes":"2023.8.21 PV def updated for 'No Value Exists'. ak","unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"6272292","version":"1","longName":"NINDS","context":"NCIP","ClassificationSchemeItems":[{"publicId":"10000330","version":"1","longName":"Treatment/Intervention Data","context":"NCIP"},{"publicId":"3151265","version":"1","longName":"Drugs","context":"NCIP"},{"publicId":"3188342","version":"1","longName":"Antithrombotics and Risk Factor Controlling Medications","context":"NCIP"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"If YES, type(s) of antiplatel","type":"Preferred Question Text","description":"If YES, type(s) of antiplatelets received.","url":null,"context":"NCIP"},{"name":"NINDS CDE Project","type":"REFERENCE","description":"NINDS CDE Project","url":"http://www.commondataelements.ninds.nih.gov/","context":"NCIP"}],"origin":"NINDS:National Institute of Neurological Disorders and Stroke Common Data Element Project","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9C048423-B928-769C-E040-BB89AD43214B","latestVersionIndicator":"Yes","beginDate":"2011-02-11","endDate":null,"createdBy":"LUY","dateCreated":"2011-02-11","modifiedBy":"SBR","dateModified":"2018-12-20","changeDescription":"5/24/18 - smt CDE transferred to NCIP ownership per NINDS (Muniza Sheikh) request.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}